Skip to main content
Figure 1 | European Journal of Medical Research

Figure 1

From: Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy

Figure 1

Time course of AQLQ for patients with asthma alone (red) and concomitant atopic dermatitis and asthma (blue). AQLQ was improved in the asthma alone group after 6 months omalizumab treatment (P < 0.05: 2 months, 3 months, 6 months and 12 months vs. baseline), while no significant change was seen in AQLQ in the atopic dermatitis/asthma group.

Back to article page

European Journal of Medical Research

ISSN: 2047-783X

Contact us